AdipoGen Life Sciences Tirzepatide novel dual GIP and GLP-1 receptor agonist

Incretins are gut-derived hormones, members of the glucagon superfamily. There are two main incretin hormones in humans: GIP (glucose-dependent insulinotropic peptide, also known as gastric inhibitory peptide) and GLP-1 (glucagon-like peptide-1). Both hormones are secreted by endocrine cells that are located in the epithelium of the small intestine and are secreted on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells.

GIP and GLP-1 exert their effects by binding to their specific receptors, the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), which belong to the G-protein-coupled receptor family. Receptor binding activates and increases the level of intracellular cyclic adenosine monophosphate in pancreatic β cells, thereby stimulating insulin secretion glucose-dependently.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which potently activates the GLP-1R signalling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Featuring glucose-lowering effects, it is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide has also been shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

To support benchwork, AdipoGen Life Sciences offers several GLP-1, GIP and glucagon agonists for obesity and type 2 diabetes research, including Liraglutide, Retatrutide, Semaglutide and Tirzepatide, which are distributed in Australia and New Zealand by Sapphire Bioscience.